These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 19251818)

  • 101. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans.
    Akabane T; Tanaka K; Irie M; Terashita S; Teramura T
    Xenobiotica; 2011 May; 41(5):372-84. PubMed ID: 21385103
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
    Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
    Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
    Vakkalagadda B; Lubin S; Reynolds L; Liang D; Marion AS; LaCreta F; Boulton DW
    Clin Ther; 2016 Aug; 38(8):1890-9. PubMed ID: 27491280
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes.
    Takasaki W; Yamamura M; Nozaki A; Nitanai T; Sasahara K; Itoh K; Tanaka Y
    Chirality; 2005 Mar; 17(3):135-41. PubMed ID: 15704197
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
    Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
    Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys.
    El Dareer SM; White VM; Chen FP; Mellet LB; Hill DL
    Cancer Treat Rep; 1977 Oct; 61(7):1269-77. PubMed ID: 412588
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.
    Ren S; Boulton DW
    Clin Pharmacol Drug Dev; 2019 May; 8(4):549-558. PubMed ID: 30500110
    [TBL] [Abstract][Full Text] [Related]  

  • 109. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
    Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
    Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
    Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
    Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
    J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
    Furuta S; Tamura M; Hirooka H; Mizuno Y; Miyoshi M; Furuta Y
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):87-96. PubMed ID: 23436178
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
    Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
    Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
    Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
    Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.
    Gombar VK; Hall SD
    J Chem Inf Model; 2013 Apr; 53(4):948-57. PubMed ID: 23451981
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Interspecies scaling of the pharmacokinetic parameters of coumarin among six different mammalian species.
    Ritschel WA; Vachharajani NN; Johnson RD; Hussain AS
    Methods Find Exp Clin Pharmacol; 1991 Dec; 13(10):697-702. PubMed ID: 1770833
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERĪ± covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Species difference in the mechanism of nonlinear pharmacokinetics of E2074, a novel sodium channel inhibitor, in rats, dogs, and monkeys.
    Nagaya Y; Takenaka O; Kusano K; Yoshimura T
    Drug Metab Dispos; 2013 May; 41(5):1004-11. PubMed ID: 23401471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.